Biotechnology giant Amgen Inc. (AMGN) is scheduled to release its second quarter 2015 results after the close on Thursday, July 30th. The company is expected to report revenue of $5.31 billion. Similarly, the EPS is projected at $2.42. A year ago, Amgen earned $2.37 a share. The Street’s estimates for the quarter reflect a year-over-year EPS and revenue increase of 2.10% and 2.50%, respectively. Meanwhile, EarningsWhisper.com reports a whisper number of $2.48 per share.
As a quick reminder, Amgen reported 1Q/15 EPS of $2.48, $0.38 better than the Street’s consensus estimate of $2.10. Revs rose 11.28% year-over-year to $5.03 billion from $4.52 billion vs. the $4.91 billion consensus.
On valuation measures, Amgen Inc. shares are currently priced at 22.92x this year’s forecasted earnings. Ticker has a PEG and forward P/E ratio of 1.59 and 16.04, respectively. Price/Sales for the same period is 6.34 while EPS is $7.41. Currently there are 10 analysts that rate AMGN a ‘Buy’, 11 rate it a ‘Hold’. No analyst rates it a ‘Sell’. AMGN has a median Wall Street price target of $183.00 with a high target of $210.00.
Over the past year, shares of Thousand Oaks, California-based firm have traded between a low of $124.76 and a high of $174.80 and are now at $169.85.
Shares are up 41.70% year-over-year and 8.75% year-to-date.